Theranostic and prognostic biomarkers: Genomic applications in urological malignancies

Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD 21231, USA.
Pathology (Impact Factor: 2.62). 06/2010; 42(4):384-94. DOI: 10.3109/00313021003779145
Source: PubMed

ABSTRACT Compared to other solid tumours such as breast, colon, and lung, the current clinical management of urological malignancies is lagging behind in terms of utilisation of clinically robust molecular tests that can identify patients that are more likely to respond to a given targeted agent, or even those in need of a more aggressive treatment approach based on well-validated molecular prognosticators. Several promising biomarkers for detection, prognosis, and targeted therapeutics are now under evaluation. The following review discusses some of the candidate biomarkers that may soon make their transition into clinically applicable assays in urological oncology patients.

1 Follower
  • [Show abstract] [Hide abstract]
    ABSTRACT: 1.8 V-only 16 Mb CMOS divided-bit line-NOR (DINOR) flash memory with alternating background-operation (BGO) capability has 72 ns random access time. The EGO feature allows program or erase in one bank while the device simultaneously allows read in the other bank. This BGO feature is suitable for mobile and personal computing, and communication products. This memory is fabricated using a 0.25 μm-design-rule, triple-layer-metal, triplewell CMOS. The cell is 0.80×0.85 μm <sup>2</sup> and the chip is 4.93×5.88 mm<sup>2</sup>
    Solid-State Circuits Conference, 1999. Digest of Technical Papers. ISSCC. 1999 IEEE International; 02/1999
  • Pathology 06/2010; 42(4):317-8. DOI:10.3109/00313021003768338 · 2.62 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Bladder cancer comprises a heterogeneous group of tumors, the majority of which are non-muscle-invasive bladder cancer (NMIBC) at initial presentation. Low-risk bladder cancer--defined as pTa low-grade papillary tumors--is the type of NMIBC with the most favorable oncologic outcome. Although the risk of progression is less than 1% in 5 years, almost 15% will recur after 1 year, and 32% after 5 years. A complete transurethral resection, followed by an immediate single postoperative instillation of chemotherapy will reduce the risk of recurrence for the first 2 years. Follow-up cystoscopy is required to detect recurrence; in the vast majority of cases the recurrent tumor is of the same stage and grade as the primary tumor. The first follow-up visit, 3 months after surgery, is the most important in predicting risk of recurrence for the future. Recent developments in profiling urine and cancer tissue make it possible to better predict risk of progression and recurrence. In the future this profiling will play an important role in the timing and the choice of treatment, as well as guiding follow-up procedures.
    Nature Reviews Urology 01/2011; 8(1):42-9. DOI:10.1038/nrurol.2010.208 · 4.52 Impact Factor
Show more